NEW YORK, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Veteran business journalist Carmen Roberts joins Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer, Regulus Therapeutics Inc. to discuss the company's industry, strategy, financials and positioning. Regulus successfully completed its Initial Public Offering in October 2012 and is listed on The NASDAQ Global Market under the symbol "RGLS."
Click here to view video:
Kleanthis G. Xanthopoulos, Ph.D.
Regulus Therapeutics Inc. [RGLS]
President and Chief Executive Officer and member of the Board of Directors
Kleanthis G. Xanthopoulos, Ph.D., Regulus' President and Chief Executive Officer, is an entrepreneur who has been involved in founding several companies. He joined Regulus around the company's formation in 2007. Prior to joining Regulus, he was a managing director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc.from its inception in 2000 to 2006, and remained a Director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals) from 1997 to 2000. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of the Biotechnology Industry Organization (BIO), Apricus Biosciences (NASDAQ: APRI), Sente Inc., and a member of the board of BIOCOM, Southern California's life science industry association.
Regulus Therapeutics [RGLS]:
Regulus Therapeutics Inc. (Nasdaq:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals (Nasdaq:ALNY) and Isis Pharmaceuticals (Nasdaq:ISIS). Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.
For more information, please visit http://www.regulusrx.com.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839
Source: NASDAQ CEO Signature Series; Regulus Therapeutics